Vinblastine, bleomycin, and methotrexate chemotherapy plus extended-field radiotherapy in early, favorably presenting, clinically staged Hodgkin's patients: the Gruppo Italiano per lo Studio dei Linfomi Experience.

• DOI: 10.1200/jco.1996.14.2.527
• Publication Date: 2017-02-24T09:46:37Z
• Authors: P G Gobbi; C Pieresca; A Frassoldati; M Carotenuto; N Di Renzo; A La Sala; R Berté; P Avanzini; M Federico; V Silingardi; E Ascari
• Keywords: Pulmonary toxicity; Regimen

PURPOSE To ascertain whether vinblastine, bleomycin, and methotrexate (VBM) (CT) combined with extended-field radiotherapy (EF RT) is effective enough to spare laparotomy in early, favorably presenting Hodgkin's disease (HD) patients. PATIENTS AND METHODS Fifty patients clinical stage IA or IIA HD favorable histology no bulky masses entered a prospective multicenter study started January 1988. The median follow-up time was 38 months. RESULTS All achieved complete remission (CR). Five relapsed after 3 40 months underwent successful salvage therapy. actuarial rate 0.89% at years 0.82% 5 years. Two died CR: one of severe pulmonary toxicity, the other second neoplasia (adenocarcinoma lung), 2 43 end therapy, respectively. hematologic toxicity recorded during VBM CT mild on whole. Major represented by side effects neurologic symptoms. Multiple regression analysis demonstrated that significantly related only amount RT delivered mediastinum not relative dose dose-intensities three drugs regimen, patient age sex. same statistical technique showed factor grade neurotoxicity vinblastine dosage. CONCLUSION EF an treatment for clinically staged, However, this combination suggests certain modifications should be evaluated.